Lilly/Icos Cialis Marketing Plan Will Target Four Million Former Viagra Users
Executive Summary
Marketing efforts for Lilly/Icos' pending erectile dysfunction treatment Cialis will target the approximately four million patients who have discontinued Pfizer's Viagra (sildenafil).
You may also be interested in...
Lilly Supports Cialis Spontaneity With Internet Trial, Direct Patient Data
Lilly's program to create a "spontaneity" advantage for its erectile dysfunction drug Cialis includes a Phase IIIb trial with direct patient observation reports from an electronic reporting system developed by the California clinical trials firm, 1747, Inc
Lilly Supports Cialis Spontaneity With Internet Trial, Direct Patient Data
Lilly's program to create a "spontaneity" advantage for its erectile dysfunction drug Cialis includes a Phase IIIb trial with direct patient observation reports from an electronic reporting system developed by the California clinical trials firm, 1747, Inc
Viagra vs. Cialis?
Twenty-four hour duration in erectile responsiveness for Lilly/Icos' Cialis "may or may not be a good thing...in light of the nitrate interaction" with phosphodiesterase inhibitors, McKinnell cautions. Meanwhile, Pfizer CEO acknowledges that Cialis' 16 minutes to onset of action "does appear to be maybe faster by one hour" than Viagra, but questions whether the difference is meaningful
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: